23rd Annual Cancer Progress Conference
March 6 & 7, 2012
The Westin New York at Times Square

AGENDA

Tuesday, March 6, 2012
7:00am  Continental Breakfast and Registration- Majestic Foyer
8:15 - 8:45am  Opening Remarks
   Jeff Bockman, PhD, Vice President, Defined Health
8:45 - 9:45am  Future of cancer therapy – Where have we been, where are we going?
   Moderator: Neal Rosen, MD, Professor of Medicine, Memorial Sloan-Kettering Cancer Center
   Panelists:
   - Steven Averbuch, MD, Vice President, Early Global Clinical Research Oncology & Head, Pharmacodiagnostics, Bristol-Myers Squibb Company
   - Larry Norton, MD, Deputy Physician-in-Chief for Breast Cancer Programs; Medical Director, Evelyn H. Lauder Breast Center; Norna S. Sarofim Chair in Clinical Oncology, Memorial Sloan-Kettering Cancer Center
   - Geert Kolvenbag MD, PhD, Global Product Vice President, AstraZeneca
9:45 - 10:30am  Keynote address: Angiogenesis
   George D. Yancopoulos, MD, PhD, Executive Vice President, Chief Scientific Officer, and President, Regeneron Research Laboratories
10:30- 10:45am  Networking Break
10:45 - 11:45am  Novel approaches in cancer drug development and clinical trials – Are we adapting and adopting fast enough?

Moderator: Jamie Freedman, MD, PhD, Vice President, Cancer Research, Oncology, GlaxoSmithKline

Panelists:
- Richard Gaynor, MD, Vice President, Cancer Research & Global Oncology Platform Leader, Eli Lilly and Company
- Eric Rowinsky, MD, Chief Medical Officer, Head of Research and Development, Executive Vice President of Stemline Therapeutics
- Robert Iannone, MD, Section Head, Oncology Clinical Research, Merck Research Laboratories

11:45 - 12:45pm  Immunotherapy for cancer – Are we there yet? The Rights and wrongs of developing next generation immunotherapies

Moderator: Mary L. (Nora) Disis, MD, Associate Dean of Translational Health Sciences, Professor of Medicine and Adjunct Professor of Pathology and Obstetrics and Gynecology, University of Washington School of Medicine, Member of the Fred Hutchinson Cancer Research Center

Panelists:
- Jedd Wolchok, MD, PhD, Associate Attending Physician, Memorial Sloan-Kettering Cancer Center
- H. Kim Lyerly MD, FACS, George Barth Gellar Professor of Cancer Research, Professor of Surgery, Associate Professor of Pathology, Assistant Professor of Immunology, Duke University School of Medicine
- Jon Wigginton, MD, Executive Director, Therapeutic Area Head, Discovery-Medicine Immuno-Oncology, Bristol-Myers Squibb Company
- James Trager, PhD, Sr. Director, Research, Dendreon Corporation
12:45 - 2:00pm  Networking Luncheon

2:00 - 3:00pm  Apoptosis – Why has drug development in apoptosis been stymied?

Moderator: Douglas R. Green, PhD, Chair, Immunology, St. Jude Children's Research Hospital

Panelists:
- Tak Mak, PhD, Director, The Campbell Family Institute for Breast Cancer Research, Ontario Cancer Institute; University Professor, University of Toronto
- David Weng, MD, PhD, Chief Medical Officer, TetraLogic Pharmaceuticals
- John C. Reed, MD, PhD, CEO, Professor and Donald Bren Chief Executive Chair, Apoptosis and Cell Death Research, Sanford-Burnham Medical Research Institute

3:00 - 4:00pm  Data, data everywhere – Generating, harvesting, and analyzing the vast fields of cancer information

Moderator: Colin Hill, Chief Executive Officer, President & Chairman, GNS Healthcare

Panelists:
- Eric Schadt, PhD, Chief Scientific Officer, Pacific Biosciences
- Alexis Borisy, Partner, Third Rock Ventures
- Bryan M. Dechairo, PhD, Senior Director, Extramural R&D Head, Medco Health Solutions

4:00 - 4:30pm  Networking Break
4:30 - 5:30pm  Melanoma: Tackling the intractable – But what next?

Moderator: Danny Welch, PhD, Associate Director of Basic Science, KU Cancer Center, Professor & Chair of Cancer Biology, Kansas Bioscience Authority Eminent Scholar, The Kansas University Medical Center

Panelists:
- Jedd Wolchok, MD, PhD, Associate Attending Physician, Memorial Sloan-Kettering Cancer Center
- Paul Chapman, MD, Professor of Medicine, Weill Cornell Medical College, Attending Physician, Memorial Sloan-Kettering Cancer Center
- David E. Fisher, MD, PhD, Chief, Department of Dermatology, Director, Melanoma Program, MGH Cancer Center, Director, Cutaneous Biology Research Center, Massachusetts General Hospital, Edward Wigglesworth Professor of Dermatology - Harvard Medical School

5:30 - 7:00pm  Reception sponsored by National Foundation for Cancer Research

7:00 - 9:00pm  National Foundation for Cancer Research Annual Svent-Gyorgyi Awards Dinner

Wednesday, March 7, 2012

7:00am  Continental Breakfast and Registration- Majestic Foyer

8:00 - 8:15am  Opening Remarks

Mike Rice, Senior Consultant, Defined Health

8:15 - 8:45am  Keynote: Hematology state of the art

Kenneth C. Anderson, MD, Director, Clinical Research, Kraft Family Professor of Medicine, Harvard Medical School, LeBow Institute for Myeloma Therapeutics & Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute
8:45 – 9:45am  Ovarian Cancer: Response followed by relapse – When will we shift the paradigm?

Moderator: Laura K. Shawver, PhD, Founder, The Clearity Foundation

Panelists:

- Robert C. Bast, Jr., MD, Vice President for Translational Research, The University of Texas MD Anderson Cancer Center
- Douglas A. Levine, MD, Head, Gynecology Research Laboratory, Associate Attending Surgeon, Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center
- Geert Kolvenbag MD PhD, Global Product VP, Olaparib, AstraZeneca

9:45 – 10:45am  Novel MOAs and targets for cancer drug development – What’s hot off the presses?

Moderator:  Jeremy Goldberg, President, JPG Healthcare LLC

Panelists:

- Robert J Schneider, PhD, Associate Director, NYU Cancer Institute Director, Translational Cancer Research Co-director, Breast Cancer Research Program
- Paul B. Fisher, MPh, PhD, Professor and Chairman, Department of Human & Molecular Genetics, Founding Director, VCU Institute of Molecular Medicine, VCU School of Medicine, Thelma Newmeyer Corman Chair in Cancer Research, VCU Massey Cancer Center
- Carlo M. Croce, MD, The John W. Wolfe Chair in Human Cancer Genetics, The Ohio State University, Chairman, Dept. of Molecular Virology, Immunology and Medical Genetics, Director, Institute of Genetics
- Philip W. Kantoff, MD, Chief Clinical Research Officer, Chief, Division of Solid Tumor Oncology, Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School
10:45 - 11:15am Networking Break

11:15 - 12:15pm ROI in cancer -- How successful has drug discovery and development been in cancer?

Moderator: Mark J. Simon, Advisor, Torreya Partners LLC

Panelists:
- George S. Golumbeski, PhD, Senior Vice President, Business Development, Celgene Corporation
- Julio Gagne, Director Portfolio & Asset Strategy, Oncology & Immunology, Bristol-Myers Squibb Company
- Srinivas Akkaraju, MD, PhD, Managing Director, New Leaf Venture Partners

12:15 - 1:30pm Networking Luncheon

1:30 - 2:30pm Comparative effectiveness and reimbursement – Are we setting the bar sufficiently high? From Proof of Concept to Proof of Relevance

Panelists:
- Debra Schrag, MD, Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute
- Bryan M. Dechairo, PhD, Senior Director, Extramural R&D Head, Medco Health Solutions
- Usman Iqbal, MD, MPH, MBA, Director, Oncology-Global Evidence & Value Development (EVD), Sanofi

2:30 – 3:00pm: Keynote Speaker: Mark McClellan, MD, PhD, Director, Engelberg Center for Health Care Reform, Senior Fellow, Economic Studies, Leonard D. Schaeffer Chair in Health Policy Studies, The Brookings Institution
3:00 - 4:00pm  Biomarkers, Companion Diagnostics and Enabling Technologies and Services for Personalized Medicine

Moderator: Brian Leyland-Jones, MD, PhD, Professor of Medicine, Department of Medicine, Emory University

Panelists:

- David Litwack, Ph.D. Health Scientist & AAAS Science & Technology Policy Fellow Office of Biorepositories and Biospecimen Research National Cancer Institute
- Andrew Allen, MD, PhD, Chief Medical Officer and EVP of Clinical and Pre-Clinical Development, Clovis Oncology
- Scott D. Patterson, PhD, Executive Director, Medical Sciences, Amgen, Inc.
- Doug Ward, Vice President and General Manager, Translational Diagnostics, Ventana Medical Systems
- Gary Kelloff, MD, Special Advisor, Division of Cancer Treatment and Diagnosis, National Cancer Institute
- Steven Averbuch, MD, Vice President, Early Global Clinical Research Oncology & Head, Pharmacodiagnostics, Bristol-Myers Squibb Company

4:00pm  Closing Remarks
4:15pm  Conference Concludes
Thank you to all of the 23rd Annual Cancer Progress Conference Sponsors and Supporters

**Sponsors**

- astellas ONCOLOGY
- Bristol-Myers Squibb
- Eisai
- Genentech
- GNS HEALTHCARE
- Lilly
- Janssen

For further information concerning Lilly grant funding visit www.lillygrantoffice.com

**Supporting Organizations**

- BioCentury
- National Foundation for Cancer Research
- Thomson Reuters
- RECAP by Deloitte